Publications:
A selected list of publications:
Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, Dekernion JB, Belldegrun AS
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker
Int J Cancer,
2005; 114(2):
268-73.
Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. ,
2004; 22(16):
3316-22.
Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS
Using protein expressions to predict survival in clear cell renal carcinoma
Clinical cancer research : an official journal of the American Association for Cancer Research. ,
2004; 10(16):
5464-71.
Han KR, Janzen NK, McWhorter VC, Kim HL, Pantuck AJ, Zisman A, Figlin RA, Dorey FJ, Said JW, Belldegrun AS
Cystic renal cell carcinoma: biology and clinical behavior
Urologic oncology. ,
2004; 22(5):
410-4.
Pantuck AJ, Van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA
Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer
Journal of immunotherapy (Hagerstown, Md. : 1997) ,
2004; 27(3):
240-53.
Patard JJ, Dorey FJ, Cindolo L, Ficarra V, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Belldegrun AS, Pantuck AJ
Symptoms As Well As Tumor Size Provide Prognostic Information On Patients With Localized Renal Tumors
J Urol,
2004; 172(6, Part 1 of 2):
2167-2171.
Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma
The Journal of urology. ,
2004; 171(6 Pt 1):
2461-6.
Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience
The Journal of urology. ,
2004; 171(6 Pt 1):
2181-5, quiz 2435.
Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA
Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma
Clinical cancer research : an official journal of the American Association for Cancer Research. ,
2004; 10(8):
2659-69.
Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS
Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population
The Journal of urology. ,
2003; 170(6 Pt 1):
2221-4.
Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience
The Journal of urology. ,
2003; 170(4 Pt 1):
1126-30.
Zisman A, Pantuck AJ, Bui MH, Said JW, Caliliw RR, Rao N, Shintaku P, Berger F, Gambhir SS, Belldegrun AS
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen
Cancer research. ,
2003; 63(16):
4952-9.
Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA
A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma
Journal of immunotherapy (Hagerstown, Md. : 1997) ,
2003; 26(5):
412-9.
Hernandez JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS
Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene
Clin Cancer Res,
2003; 9(5):
1906-16.
Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin RA, Belldegrun AS
TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion
J Urol,
2003; 169(3):
899-903; discussion 903-4.
Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS
Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system
Prostate,
2003; 55(4):
299-307.
Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS
Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer
The Prostate. ,
2003; 55(1):
71-80.
Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS
Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy
The Journal of urology. ,
2003; 169(3):
909-16.
Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
Clinical cancer research : an official journal of the American Association for Cancer Research. ,
2003; 9(2):
802-11.
Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS
Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
Urology. ,
2003; 61(2):
314-9.